Navigation Links
Epeius Biotechnologies' REXIN-G, a Tumor-Targeted Genetic Medicine for Metastatic Cancer, Gains Phase 3 Product Designation From the U.S. FDA
Date:2/28/2011

SAN MARINO, Calif., Feb. 28, 2011 /PRNewswire/ -- Epeius Biotechnologies (www.epeiusbiotech.com) announced today that the U.S. FDA has granted Phase 3 status for the Company's lead anti-cancer agent, Rexin-G, the first, and so far only, targeted gene delivery system developed to seek out and destroy metastatic cancer. According to Dr. Maria Gordon, Chief Medical Officer of Epeius, "What this means, in terms of clinical development, is that the Rexin-G product, with its advanced GMP manufacturing, bio-processing, and final formulation, meets rigorous FDA standards for obtaining a marketing license in the future; and that Epeius Biotech can now proceed with its strategic, diversified Phase 3 drug development program for pancreatic cancer, osteosarcoma and soft tissue sarcoma."

In addition to these high-priority programs, Rexin-G has demonstrated significant anti-tumor activity in chemotherapy-resistant breast cancer, hormone-refractory prostate cancer, ovarian cancer, squamous cell carcinoma, and certain hematologic malignancies, such as large B-cell lymphoma.

Rexin-G® was granted accelerated approval for the treatment of all chemotherapy-resistant solid malignancies in the Republic of the Philippines in 2007. In the U.S.A., Rexin-G gained Orphan Drug Designation and market protections from the FDA for pancreatic cancer in 2003, followed by Orphan Drug Status for both osteosarcoma and soft tissue sarcoma in 2008.  More recently, Epeius Biotechnologies completed a series of Phase 1 and Phase 2 clinical trials in the U.S., establishing the thresholds for bioactivity and dose-dependent efficacy for Rexin-G against a number of otherwise intractable cancers, as well as the product's overall safety over extended survival times and a notable lack of either safety issues or dose
'/>"/>

SOURCE Epeius Biotechnologies Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Epeius Biotechnologies Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy
2. Epeius Biotechnologies Corporation Expands its Rexin-G Production Facilities in Southern California
3. Epeius Biotechnologies to Partner at BIO Investor Forum
4. Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
5. Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
6. Targeting Metastatic Cancer From the Inside: Epeius Biotech Reveals a New Generation of Tools for Medical Gene Delivery
7. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
8. Reportlinker Adds Nanobiotechnologies- applications, markets and companies
9. TriLink BioTechnologies Launches CleanAmp™ 7-deaza-dGTP for GC-rich Target Amplification
10. Maven Biotechnologies Receives $1.96 Million From the National Institutes of Health (NIH) to Develop Their LFIRE™ Label-Free Detection Technology for Proteomics
11. Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... A newly launched business ... to lower the barriers to innovation in life sciences R&D. The Pistoia Alliance President’s ... cash prizes of US$15,000 and a period of expert mentorship from a senior industry ...
(Date:7/1/2015)... ... July 01, 2015 , ... Apex Therapeutics announced today that company ... Philadelphia, PA. , The presentation took place on Tuesday, June 16 and ... the development of APX3330 for the treatment of pancreatic cancer. A copy of ...
(Date:7/1/2015)... NEW YORK , July 1, 2015 /PRNewswire/ ... G ), a global leader in designing, ... the Aecus Innovation Award in recognition of their ... operational efficiencies in UCB,s global business services (GBS) ... acknowledge service providers and clients that work together ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... to take part in the first half of “Integrative Biotechnology,” an applied biotechnology ... established in summer 2014, this course combines students from both universities and is ...
Breaking Biology Technology:Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2
... OAKS, Calif., June 24, 2011 Amgen (NASDAQ: ... Medicinal Products for Human Use (CHMP) of the European ... that Vectibix® (panitumumab) be approved for use in the ... and in second-line in combination with FOLFIRI in patients ...
... are exposed to light, they blink in a ... at the University of Pennsylvania have shown that ... new insight into this mysterious blinking behavior. ... Drndic,s group, including graduate student Siying Wang and ...
... BioNeutral Group Inc., (OTCBB: BONU.ob) today announced it ... of their revolutionary Cold Sterilant and Cleaning/Odor Products ... selected by New Jersey based T.U.C.S. Cleaning Services ... distribution company, because of the superior effectiveness of ...
Cached Biology Technology:Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 2Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 3Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 4Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 5Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 6Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 7Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 8Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 9Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 10Penn physicists observe 'campfire effect' in blinking nanorod semiconductors 2Penn physicists observe 'campfire effect' in blinking nanorod semiconductors 3BioNeutral Starts Commercial Deployment of Its Ygiene 206 Sterilant and Ogiene Products Within Port Authority Facilities Using T.U.C.S. Cleaning Services 2BioNeutral Starts Commercial Deployment of Its Ygiene 206 Sterilant and Ogiene Products Within Port Authority Facilities Using T.U.C.S. Cleaning Services 3BioNeutral Starts Commercial Deployment of Its Ygiene 206 Sterilant and Ogiene Products Within Port Authority Facilities Using T.U.C.S. Cleaning Services 4
(Date:6/30/2015)... June 30, 2015 To bolster its efforts and ... Corp. announced today the addition of two new team members. ... board advisor and David Raviv will act as ... HYPR Corp.,s commitment to providing the most secure solutions for ... co-founded Layer 7 Technologies, a provider of security and ...
(Date:6/30/2015)... 2015 Genisphere announced Tom ... help further develop Genisphere,s therapeutics capabilities and portfolio. Mr. ... spent much of the last 25 years in leadership ... and Johnson & Johnson. Tom started his career in ... Corporate Finance. He graduated from Dartmouth College with a ...
(Date:6/29/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ) ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... America Biomedical Sensors market is estimated at $0.65 billion ... period 2014-2020 The near future will bring ... of each individual. These sensors can be set to ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Latin America Biomedical Sensors Market Report 2015-2020 2
... from the Luxembourg Centre for Systems Biomedicine (LCSB) of ... in the brain can produce a substance that prevents ... assumed that only certain fungi produced itaconic acid. A ... Metabolomics Group at LCSB, and Dr. Alessandro Michelucci has ...
... reporting new outbreaks and the increased spread of Cassava Brown ... virus could cause a 50 percent drop in production of ... income for 300 million Africans. , The "pandemic" of ... been looking to the otherwise resilient cassava plantwhich is also ...
... scientists, writing in the journal Nature Geoscience , have ... an unexpected cooling effect on the world,s climate by making ... on to tiny particles suspended in the air. When the ... It has been known for some decades that the number ...
Cached Biology News:LCSB discovers endogenous antibiotic in the brain 2Scientists alarmed by rapid spread of Brown Streak Disease in cassava 2Scientists alarmed by rapid spread of Brown Streak Disease in cassava 3Scientists alarmed by rapid spread of Brown Streak Disease in cassava 4Organic vapors affect clouds leading to previously unidentified climate cooling 2
Mouse monoclonal [2Q2147] to Aequorin ( Abpromise for all tested applications)....
Phosphotyrosine IgG mouse monoclonal antibody: Alkaline Phosphatase conjugate...
... Although the mixed TAMRA isomers are ... isomers are increasingly preferred for labeling peptides ... in HPLC purification that is often required ... often used than 6-TAMRA for labeling peptides ...
anti-Lactate Dehydrogenase...
Biology Products: